NewLink Genetics (NASDAQ: NLNK) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare NewLink Genetics to similar businesses based on the strength of its dividends, profitability, analyst recommendations, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of recent recommendations for NewLink Genetics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics 0 0 6 0 3.00
NewLink Genetics Competitors 540 2467 6687 126 2.65

NewLink Genetics presently has a consensus price target of $25.67, suggesting a potential upside of 201.61%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.69%. Given NewLink Genetics’ stronger consensus rating and higher possible upside, equities analysts plainly believe NewLink Genetics is more favorable than its competitors.


This table compares NewLink Genetics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics -229.19% -63.39% -47.83%
NewLink Genetics Competitors -3,262.51% -525.94% -39.29%

Insider & Institutional Ownership

52.7% of NewLink Genetics shares are held by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.7% of NewLink Genetics shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares NewLink Genetics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NewLink Genetics $35.77 million -$85.15 million -3.49
NewLink Genetics Competitors $217.29 million -$39.39 million -64.96

NewLink Genetics’ competitors have higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

NewLink Genetics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, NewLink Genetics’ competitors have a beta of 1.57, indicating that their average stock price is 57% more volatile than the S&P 500.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with's FREE daily email newsletter.